Sfoglia per Rivista HEPATOLOGY
Receptors of calcium and calcimimetic agents inside the cirrotic liver are new targets to reduce portal pressure.
2010-01-01 Sansoè G;Aragno M; Tommasinelli C.E; Parola M.
Recombinant interferon-alfa therapy in children with chronic hepatitis C.
1995-01-01 Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A
Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.
1994-01-01 Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T
Reduced liver injury is associated with diminished oxidative stress in monocyte chemoattractan protein-1(MCP-1)-deficient mice
2004-01-01 Parola M; Aleffi S; Petrai I; Aragno M; Mastrocola R; Zamara E; Novo E; Delogu W; DeFranco R; Pinzani M; Rollins BJ; Marra F.
Regulation of rat hepatocyte protein kinase C beta isoenzymes by the lipid peroxidation product 4-hydroxy-2,3-nonenal: A signaling pathway to modulate vesicular transport of glycoproteins.
1999-01-01 CHIARPOTTO E; DOMENICOTTI C; PAOLA D; VITALI A; NITTI M; PRONZATO MA; BIASI F; COTTALASSO D; MARINARI UM; DRAGONETTI A; CESARO P; ISIDORO C; POLI G
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
2004-01-01 Bugianesi E; Manzini P; D'Antico S; Vanni E; Longo F; Leone N; Massarenti P; Piga A; Marchesini G; Rizzetto M
Release of hepatocyte-derived microparticles dueing lipotoxicity induces angiogenesis.
2011-01-01 Povero D; Berk MP; Mulya A; Thapaliya S; Parola M; Feldstein AE.
Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD
2016-01-01 Pelusi, Serena; Petta, Salvatore; Rosso, Chiara; Borroni, Vittorio; Fracanzani, Anna Ludovica; Dongiovanni, Paola; Craxi, Antonio; Bugianesi, Elisabetta; Fargion, Silvia; Valenti, Luca
Reperfusion damage to the bile canaliculi in transplanted human liver.
1996-01-01 CUTRIN JC; CANTINO D; BIASI F; CHIARPOTTO E; SALIZZONI M; ANDORNO E; MASSANO G; LANFRANCO G; RIZZETTO M; BOVERIS A; POLI G
Reply
2018-01-01 Gaggini, Melania; Bugianesi, Elisabetta; Gastaldelli, Amalia
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4.
2011-01-01 D'Avolio A; Ciancio A; Siccardi M; Baietto L; Simiele M; Cariti G; Calcagno A; Smedile A; Cusato J; Bonora S; Rizzetto M; Di Perri G.
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria
2024-01-01 Pennisi, Grazia; Enea, Marco; Romero-Gomez, Manuel; Bugianesi, Elisabetta; Wai-Sun Wong, Vincent; Fracanzani, Anna Ludovica; de Ledinghen, Victor; George, Jacob; Berzigotti, Annalisa; Viganò, Mauro; Sebastiani, Giada; Cannella, Roberto; Delamarre, Adèle; Di Maria, Gabriele; Lange, Naomi F; Tulone, Adele; Di Marco, Vito; Cammà, Calogero; Petta, Salvatore
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity
2009-01-01 A.L. Fracanzani; L. Valenti; E. Bugianesi; E. Vanni; L. Miele; C. Bertelli; E. Fatta; A. Grieco; G. Marchesini; S. Fargion
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
2008-01-01 Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S.
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
1998-01-01 Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G.
Serial passage of hepatitis delta virus in chronic hepatitis B carrier chimpanzees
1988-01-01 A. PONZETTO; F. NEGRO; H. POPPER; F. BONINO; R. ENGLE; M. RIZZETTO; R.H. PURCELL; J.L. GERIN
Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees.
1988-01-01 PONZETTO A ;NEGRO F ;POPPER H ;BONINO F ;ENGLE R ;RIZZETTO M ;PURCELL RH ;GERIN JL
Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation.
1998-01-01 BORGHESIO E ;ROSINA F ;SMEDILE A ;LAGGET M ;NIRO MG ;MARINUCCI G ;RIZZETTO M
SIRT and chemotherapy in unresectable iCCA: Ready to take off
2024-01-01 Bargellini I.; Rimassa L.; Masi G.
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
2009-01-01 Vanni E; Abate ML; Gentilcore E; Hickman I; Gambino R; Cassader M; Smedile A; Ferrannini E; Rizzetto M; Marchesini G; Gastaldelli A; Bugianesi E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Receptors of calcium and calcimimetic agents inside the cirrotic liver are new targets to reduce portal pressure. | 2010 | Sansoè G;Aragno M; Tommasinelli C.E; Parola M. | |
| Recombinant interferon-alfa therapy in children with chronic hepatitis C. | 1995 | Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A | |
| Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. | 1994 | Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T | |
| Reduced liver injury is associated with diminished oxidative stress in monocyte chemoattractan protein-1(MCP-1)-deficient mice | 2004 | Parola M; Aleffi S; Petrai I; Aragno M; Mastrocola R; Zamara E; Novo E; Delogu W; DeFranco R; Pinzani M; Rollins BJ; Marra F. | |
| Regulation of rat hepatocyte protein kinase C beta isoenzymes by the lipid peroxidation product 4-hydroxy-2,3-nonenal: A signaling pathway to modulate vesicular transport of glycoproteins. | 1999 | CHIARPOTTO E; DOMENICOTTI C; PAOLA D; VITALI A; NITTI M; PRONZATO MA; BIASI F; COTTALASSO D; MARINARI UM; DRAGONETTI A; CESARO P; ISIDORO C; POLI G | |
| Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver | 2004 | Bugianesi E; Manzini P; D'Antico S; Vanni E; Longo F; Leone N; Massarenti P; Piga A; Marchesini G; Rizzetto M | |
| Release of hepatocyte-derived microparticles dueing lipotoxicity induces angiogenesis. | 2011 | Povero D; Berk MP; Mulya A; Thapaliya S; Parola M; Feldstein AE. | |
| Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD | 2016 | Pelusi, Serena; Petta, Salvatore; Rosso, Chiara; Borroni, Vittorio; Fracanzani, Anna Ludovica; Dongiovanni, Paola; Craxi, Antonio; Bugianesi, Elisabetta; Fargion, Silvia; Valenti, Luca | |
| Reperfusion damage to the bile canaliculi in transplanted human liver. | 1996 | CUTRIN JC; CANTINO D; BIASI F; CHIARPOTTO E; SALIZZONI M; ANDORNO E; MASSANO G; LANFRANCO G; RIZZETTO M; BOVERIS A; POLI G | |
| Reply | 2018 | Gaggini, Melania; Bugianesi, Elisabetta; Gastaldelli, Amalia | |
| Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. | 2011 | D'Avolio A; Ciancio A; Siccardi M; Baietto L; Simiele M; Cariti G; Calcagno A; Smedile A; Cusato J; Bonora S; Rizzetto M; Di Perri G. | |
| Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria | 2024 | Pennisi, Grazia; Enea, Marco; Romero-Gomez, Manuel; Bugianesi, Elisabetta; Wai-Sun Wong, Vincent; Fracanzani, Anna Ludovica; de Ledinghen, Victor; George, Jacob; Berzigotti, Annalisa; Viganò, Mauro; Sebastiani, Giada; Cannella, Roberto; Delamarre, Adèle; Di Maria, Gabriele; Lange, Naomi F; Tulone, Adele; Di Marco, Vito; Cammà, Calogero; Petta, Salvatore | |
| Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity | 2009 | A.L. Fracanzani; L. Valenti; E. Bugianesi; E. Vanni; L. Miele; C. Bertelli; E. Fatta; A. Grieco; G. Marchesini; S. Fargion | |
| Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes | 2008 | Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S. | |
| Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. | 1998 | Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G. | |
| Serial passage of hepatitis delta virus in chronic hepatitis B carrier chimpanzees | 1988 | A. PONZETTO; F. NEGRO; H. POPPER; F. BONINO; R. ENGLE; M. RIZZETTO; R.H. PURCELL; J.L. GERIN | |
| Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees. | 1988 | PONZETTO A ;NEGRO F ;POPPER H ;BONINO F ;ENGLE R ;RIZZETTO M ;PURCELL RH ;GERIN JL | |
| Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. | 1998 | BORGHESIO E ;ROSINA F ;SMEDILE A ;LAGGET M ;NIRO MG ;MARINUCCI G ;RIZZETTO M | |
| SIRT and chemotherapy in unresectable iCCA: Ready to take off | 2024 | Bargellini I.; Rimassa L.; Masi G. | |
| Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C | 2009 | Vanni E; Abate ML; Gentilcore E; Hickman I; Gambino R; Cassader M; Smedile A; Ferrannini E; Rizzetto M; Marchesini G; Gastaldelli A; Bugianesi E. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile